![](/wp-content/uploads/2018/10/cd1qIzvuRCS0ubDS29lY.png)
$599
Tandem Q3 ’19 Earnings Update
Tandem Diabetes Care hosted its Q3 ’19 earnings call and provided updates to its diabetes business including the regulatory status of t:slim X2 with Control IQ (hybrid closed loop) and development status of its t:sport. Below, FENIX provides highlights and insights from the call.